982: Evaluation of Efficacy of Fasaret in Dogs with Osteosarcoma

Grant Status: Closed

Grant Amount: $199,692
Don Bellgrau, Ph.D.; ApopLogic Pharmaceuticals, LLC
April 1, 2008 - March 31, 2010

Sponsor(s): Akita Club of America, Inc., American Boxer Charitable Foundation, American Bullmastiff Association, Briard Club of America Health & Education Trust, Central New Jersey Hound Association, Flat-Coated Retriever Foundation, German Wirehaired Pointer Club of America, Golden Retriever Foundation, Great Pyrenees Club of America, Greyhound Club of America, Leonberger Health Foundation, Mastiff Club of America, Rottweiler Health Foundation, St. Bernard Club of America, Starlight Fund

Breed(s): -All Dogs
Research Program Area: Oncology - Osteosarcoma
Donate to Support this Research Program Area

Project Summary

The goal of this study is to establish efficacy of Fasaret in treating osteosarcoma in canine companion animals. Fasaret is a human adenovirus vector encoding Fas ligand (FasL), a molecule that binds to a "death receptor" called Fas (CD95) that is often highly up-regulated on rapidly dividing cells such as cancers, leukemias, and lymphomas, and on activated white blood cells. Under the appropriate circumstances, engagement of the Fas receptor by FasL induces programmed cell death. Osteosarcoma predominantly affects larger canine breeds. Spontaneous canine osteosarcoma is also very similar to human osteosarcoma, which, when diagnosed, occurs during childhood. This study involves administering Fasaret to dogs at the time of bone biopsy, 10 days prior to limb amputation, should the biopsy confirm a diagnosis of osteosarcoma. Dogs receive standard of care in addition to treatment with Fasaret, which is limb amputation followed by chemotherapy. Dogs are examined for two years under the study, looking at specified time points for increased numbers of dogs that remain cancer free, to determine efficacy. A total of 50 dogs will be examined at the highest dose in this trial, 26 of these dogs being funded by the AKC CHF. All 26 dogs have been enrolled, 20 at CSU and 6 at UMN. The treatment has shown positive results at 90 day survival. Future studies will address improved dosing regiments.


Modiano, J. F., Bellgrau, D., Cutter, G. R., Lana, S. E., Ehrhart, N. P., Ehrhart, E., … Duke, R. C. (2012). Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer. Molecular Therapy, 20(12), 2234–2243. https://doi.org/10.1038/mt.2012.149

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.